Testagen is a synthetic short peptide from the Khavinson “bioregulator” family, marketed for testicular and male reproductive tissue support. Like Prostamax, it is among the least independently documented compounds in this product line: no PubMed-indexed study specifically confirming a “Testagen” compound, sequence, or reproductive-tissue mechanism was identified in this review, and vendor sources disagree on its exact amino-acid sequence. It is not an approved drug anywhere, and independent verification of its claimed mechanism is essentially absent.
Research snapshot
| Peptide category | Khavinson-family short “bioregulator” peptide, marketed for testicular/male reproductive tissue support |
| Primary research interest | Testicular and male reproductive tissue support (marketed; not independently confirmed) |
| Highest available evidence | Unverified — no PubMed-indexed study specifically confirming a “Testagen” compound, sequence, or reproductive-tissue mechanism was identified |
| Human research available | No — no human clinical trial identified |
| Development status | Not in formal pharmaceutical development; sold as an oral capsule or reconstituted research powder |
| Regulatory status | Not an approved drug anywhere |
| Last reviewed | September 2026 |
Technical identity
| Primary name | Testagen |
| Alternative names | Marketed as part of the Khavinson “Cytomax”/bioregulator peptide line |
| Peptide sequence | Not reliably established — vendor sources disagree on its exact amino-acid sequence, and no PubMed-indexed study confirming a “Testagen” compound was identified |
| Amino-acid length | Not reliably established |
| Molecular formula | Not independently verified in this pass |
| Molecular weight | Not independently verified in this pass |
| CAS Registry Number | Not reliably established |
| PubChem CID | Not reliably established |
| Peptide class | Khavinson-group “bioregulator”/”Cytomax” peptide line (Saint Petersburg Institute of Bioregulation and Gerontology) |
| Primary biological target | Not established — no PubMed-indexed primary research located for this named compound |
| Developer or originator | Saint Petersburg Institute of Bioregulation and Gerontology (Khavinson group), for the broader bioregulator line |
| Development status | Not an approved or registered pharmaceutical anywhere identified in this review |
What it is
Testagen is marketed as part of the Khavinson-group “Cytomax”/bioregulator peptide line developed at the Saint Petersburg Institute of Bioregulation and Gerontology, following the family’s organ-specific naming convention, here applied to the testes and male reproductive system. It is sold as an oral capsule or reconstituted research powder.
No PubMed-indexed primary research study using the name “Testagen,” and no confirmed testicular- or reproductive-tissue-specific peptide study from the Khavinson group under any sequence, was identified in this review. Vendor educational pages cite the same general Khavinson-program references used for other under-documented compounds in this family (broad gerontology and cancer-peptide reviews) rather than a study specific to reproductive tissue or this named compound.
Sourcing note: one vendor educational page describes Testagen’s sequence as “Lys-Glu-Asp-Gly” (KEDG). This is the same four-letter code that some other sources (including material reviewed for this site’s Vesugen entry) attach instead to Vesugen, and it does not match KED (Lys-Glu-Asp), the tripeptide that is well documented in the peer-reviewed literature under a different compound name. This is a genuine, unresolved cross-vendor naming conflict and should not be silently resolved in favor of either compound.
How does it work?
Plain-English explanation
The general theory behind this peptide family is that very short peptides can nudge aging cells in a specific organ toward more youthful gene activity. For Testagen, this idea has not been directly tested and confirmed in a peer-reviewed, testis-specific study identified in this review — the mechanism is inferred from the broader Khavinson bioregulator concept rather than demonstrated for this compound by name.
Technical explanation
No testis- or reproductive-tissue-specific mechanistic data (effects on Leydig cells, Sertoli cells, spermatogenesis, or testosterone-axis gene expression) attributable specifically to a compound reliably identified as Testagen were located in PubMed during this review. As with Prostamax, extrapolating unrelated Khavinson-peptide findings from skin, kidney, or stem-cell studies to a reproductive-tissue-specific claim for Testagen would not be scientifically sound, and this entry does not do so.
Potential benefits and research applications
Testicular tissue and reproductive-system support (as marketed)
What is being investigated: vendor marketing describes Testagen as supporting testicular cellular aging, reproductive tissue maintenance, and general male reproductive health. How the effect might occur: not established — no compound-specific mechanistic study was identified. Evidence: none identified specific to Testagen or confirmed testicular tissue research in PubMed during this review. Strength: has not been established.
Testosterone support (as marketed)
What is being investigated: some vendor pages associate Testagen with testosterone or broader hormonal support. How the effect might occur: not established in any source reviewed. Evidence: none identified. Strength: has not been established; there is no published mechanistic or clinical link between this compound and testosterone levels in the sources reviewed.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
Amounts studied in human research
No established or reliably sourced dosing information was identified. No human clinical trial of Testagen was located.
Amounts studied in animal research
No established or reliably sourced dosing information was identified. No confirmed, compound-specific animal dosing study was located.
Practitioner and community-reported protocols
Vendor pages selling Testagen as a 20 mg lyophilized vial describe generic rodent-study dosing in the “microgram per kilogram” range by parenteral routes, and describe an unspecified “Russian clinical record” as involving “discrete ten to twenty day courses at tens to low hundreds of micrograms,” without naming a specific trial, journal, or year that could be checked. This figure is widely repeated online, but its original source could not be verified, and no vendor page reviewed provided a checkable citation for it.
Explanation of the reported figures
As with Prostamax, the Testagen dosing claims found during this review were vague and attributed only to an unnamed “Russian clinical record” rather than a specific, checkable study, and no PubMed-indexed source could be found to confirm or add detail to them. The molecular weight figure some vendors quote (approximately 447.5 g/mol) is explicitly described by at least one vendor page as “computed from standard residue masses” rather than quoted from a paper — meaning it is a calculation based on an unverified assumed sequence, not a confirmed chemical property. The honest conclusion is that essentially nothing about Testagen dosing, sequence, or mechanism has been independently verified in this review.
What circulates E5
Vendor pages selling Testagen describe vague dosing language — generally rodent studies in the "microgram per kilogram" range by parenteral routes, and an unnamed "Russian clinical record" describing "discrete ten to twenty day courses at tens to low hundreds of micrograms" — without citing a specific, checkable study. Widely repeated online, but its original source could not be verified. No specific milligram figure, frequency, or route could be confirmed as tracing to any identifiable published source, human or animal. This should be treated as vendor-tier marketing language, not as documented dosing evidence.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Side effects, risks, and limitations
No human or confirmed animal study exists to characterize side effects for this compound specifically. As with other unregulated peptide products, purity, accurate labeling, contamination, correct concentration, and sterility are not guaranteed for vendor-sold Testagen. Essentially nothing about its safety, appropriate dose, or interactions has been independently established.
Regulatory and developmental status
Testagen has no drug approval in the United States, European Union, or Russia identified in this review. It is sold as an oral “bioregulator” supplement and research chemical, not as a registered pharmaceutical, and has not entered any recognized clinical trial pipeline identified in this review. Status verified as of the date below.
Frequently asked questions
What is Testagen?
A marketed Khavinson-family “bioregulator” peptide positioned for testicular and male reproductive support; its specific amino-acid sequence and any dedicated reproductive-tissue study could not be confirmed in this review.
What is the sequence of Testagen?
Not reliably established. At least one vendor describes it as “Lys-Glu-Asp-Gly” (KEDG), which conflicts with how other vendors label the same four-letter code for a different compound (Vesugen). No peer-reviewed source confirming any specific sequence under the name Testagen was identified.
Does Testagen affect testosterone?
No published mechanistic or clinical evidence linking this compound to testosterone levels was identified.
Has Testagen been studied in humans?
No established or reliably sourced human clinical study was identified.
What dosage circulates online?
Vendors describe vague ranges (tens to low hundreds of micrograms over 10-20 days) attributed to an unnamed “Russian clinical record.” Widely repeated online, but its original source could not be verified.
Is Testagen approved anywhere?
No. It is not an approved medicine in any jurisdiction identified in this review.
What remains unknown?
Essentially everything specific to this compound: its confirmed sequence, any dedicated reproductive-tissue mechanistic or animal study, and any verifiable human dosing figure.
Bottom line
Testagen is among the least independently documented compounds in the Khavinson bioregulator family. No PubMed-indexed, compound-specific study was identified during this review, vendor sources disagree on its sequence (including a direct conflict with how the same code is used for a different product), and the dosing figures that circulate are vague, unsourced, and in one case explicitly computed rather than measured. It should be treated as a marketed research/supplement product built on the general Khavinson bioregulator narrative rather than as a peptide with its own demonstrated evidence base.